KYOTO, Japan, Oct. 7, 2024 /PRNewswire/ -- Rege Nephro Co., Ltd. (https://www.regenephro.co.jp/) is excited to announce that the company has successfully developed a funding plan of total 25 billion yen in new Series B funding and raised 22.5 billion yen with the first payment. This significant investment brings the company's total funding to 44 billion yen. The funding round attracted a mix of strategic investors, including DCI Partners Co., Ltd. as a lead investor, JIC Venture Growth Investments Co., Ltd., Nippon Venture Capital CO., Ltd., TOHOKU University Venture Partners Co., Ltd., Golden Asia Fund Ventures Ltd., Mitsui Chemicals, Inc., Global Brain Corporation, Kyoto University Innovation Capital Co., Ltd., JAFCO Group Co., Ltd., Mitsubishi UFJ Capital Co., Ltd., ASAHI KASEI CORPORATION, QB Capital, LLC who recognize the potential of Rege Nephro in delivering new treatments to patients suffering from their diseases. The newly acquired funds will be strategically used to advance the clinical trials of RN-014, our promising treatment in Phase II trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD), and to prepare for clinical trials in the United States. Additionally, the funding will support the completion of preclinical trials for our second innovative product, RN-032, aimed at treating Chronic Kidney Disease (CKD) through cell therapy.
Investor Statements
DCI Partners Co., Ltd.
"We are excited to announce that we are the lead investor in this round of investment from our fund. We are fully committed to supporting the growth of Rege Nephro."
JIC Venture Growth Investments Co., Ltd.
"We strongly believe that his advanced drug discovery research based on Professor Osafune's discoveries will provide new therapeutic solutions for intractable renal diseases."
Kyoto University Innovation Capital Co., Ltd.
"We are delighted that Rege Nephro, which we have supported since before the company was founded, has finally entered the clinical stage. We hope that this funding will accelerate the clinical trials and bring a new therapeutic drug to patients as soon as possible."
JAFCO Group Co., Ltd.
"We hope that this financing will further accelerate Rege Nephro research and development in iPS drug discovery and provide new treatment options for patients suffering from diseases with limited treatment options."
Mitsubishi UFJ Capital Co., Ltd.
"Our continued investment reflects our confidence in Rege Nephro's rapid progress and the potential of Professor Osafune's iPS cell technology to significantly impact medical practice."
Series B investors
DCI Partners Co., Ltd.
JIC Venture Growth Investments Co.,
Nippon Venture Capital CO., Ltd
TOHOKU University Venture Partners Co., Ltd.
Golden Asia Fund Ventures Ltd.
Mitsui Chemicals, Inc.
Global Brain Corporation
Kyoto University Innovation Capital Co., Ltd.
JAFCO Group Co., Ltd.
Mitsubishi UFJ Capital Co., Ltd.
QB Capital, LLC
Industrial Technology Investment
SHIMADZU CORPORATION
SCREEN Holdings Co., Ltd.
Chushin Venture Capital Co.,Ltd.
SENSHU IKEDA CAPITAL CO.,LTD.
Toyo Seikan Group Holdings, Ltd.
ASAHI KASEI CORPORATION
i-Lab CVC1 Limited Liability Partnership
Others
About Rege Nephro Co., Ltd.
Rege Nephro Co., Ltd. is a clinical-stage biotech company utilizing induced pluripotent stem cell (iPSC)-based technology from the Center for iPS Cell Research and Application (CiRA), Kyoto University. It is developing therapeutics and cell therapy for kidney, liver, and pancreas diseases.
About RN-014
Tamibarotene, under development for ADPKD, is a retinoic acid receptor (RAR) agonist expected to potently inhibit cyst formation and improve renal function. The Phase II clinical trial began in December 2023. This trial includes a pharmacokinetic (PK) phase and a randomization phase. Various safety measures have been established, including phased patient enrollment, periodic independent safety monitoring, strict criteria for dose reduction and discontinuation of the investigational drug, and criteria for discontinuation of the entire trial. There have been no significant issues at this time.
About RN-032
Cell therapy using NPCs for Chronic Kidney Disease (CKD). Nephron progenitor cells (NPCs) are cells that give rise to nephrons. Rege Nephro has been tried implanting iNPCs (NPCs induced from allogeneic human iPSCs) into the damaged kidneys, and the improvements in renal function have been confirmed in the several mouse experiments.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Rege Nephro Co., Ltd. Successfully Completes Series B Funding to Accelerate Kidney Disease Therapy Trials
SINGAPORE, Oct. 7, 2024 /PRNewswire/ -- In a landmark collaboration, Singapore Battery manufacturer Durapower Holdings Pte Ltd (Durapower) and leading Australia Zero-Emission Bus Manufacturer, ARCC, have established a business venture to pioneer the successful integration of Durapower's leading battery technology with ARCC's battery electric and hydrogen buses.
This milestone collaboration is the first of its kind for an Australia Bus Manufacturer.
ARCC's partnership with Durapower will demonstrate the opportunity to offer bespoke battery solutions to bus operators, with an industry-first scalable battery program that will allow for the matching of battery systems to route requirements and charging systems.
"The ability to tailor and change battery capacity on buses means operators now have an option of flexibility not previously available in the market." ARCC's Managing Director Peter Murley commented.
Durapower Group CEO Kelvin Lim said, "Durapower's launch into the Australian market with ARCC not only demonstrated the viability of zero-emission public transport but also marks the beginning of a new and innovative potential industry on Singaporean and Australian shores, with technology transfer planned between the companies." He further added that, "This promises a sustainable future as well as the potential for new economic and employment opportunities in both countries."
Mr Lim said, "Durapower and ARCC are keen to demonstrate how the collaboration between industry participants with aligned technologies has the ability to set a precedent for future green technology initiatives.", adding that, "This collaboration between us will not only support ARCC's buses, but will establish the foundation for Durapower to consider new industry opportunities in Australia that further promise to bolster the future economy and create local jobs."
"The success of this collaboration is setting a new standard of innovation, showcasing the tangible results of combining ARCC's and Durapower technological advancements, to build world-class eco-friendly buses in Australia", Mr Murley said. "Both companies share a vision for a cleaner, greener public transport sector; our joint dedication to pioneering new solutions has been the catalyst for advancing local innovation into practical vehicle-based solutions."
"The Durapower ARCC partnership advances a sustainable technical solution that not only addresses climate change but also supports economic growth and job creation." Mr Murley commented. "By supporting initiatives like this, we're not just contributing to our climate goals but also securing a prosperous, job-rich future for the next generation."
Mr Lim remarked, "The partnership with ARCC is a model we believe will inspire further collaboration between the businesses in the sector, amplifying the growth and impact on the industry and the environment."
The official launch of the Durapower ARCC collaboration is on 7th October 2024, at Durapower's Singapore office.
About Australian Aluminium Revolutionary Chassis Company (arccaus.com.au)
ARCC is the foremost Australian zero-emission transport company, committed to the development of local manufacturing and expertise. The company supports all levels of the industry by providing end-to-end solutions for the decarbonisation of fleets and have successfully delivered multiple projects while managing design, production, energy supply, and government approvals for our customers.
ARCC's products and services include battery electric buses, hydrogen electric buses, integrated power solutions, hydrogen refuellers, fuel cell integration and support, and turnkey zero-emission vehicles.
About Durapower Group (www.durapowergroup.com)
Headquartered in Singapore, Durapower offers closed-loop, end-to-end energy storage solutions for the electric mobility and renewable energy applications including on and off-road Electric, Hybrid and Plug-in Hybrid Electric Vehicles, electric marine vessel and stationary energy storage solutions. Since 2009, Durapower has been a leading innovator of Lithium-Ion cell technology, focusing on the research and development of battery materials, battery cell manufacturing and system integration. With a global presence spanning 25 countries and 50 cities, including European Countries, China, India and Southeast Asia. Durapower Group strives to make scalable, sustainable batteries that support the circular economy, empowering lives and transforming the future towards a carbon neutral economy.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Driving Australia forward with landmark battery and bus business venture
